8-K: Plus Therapeutics Announces Third Quarter 2024 Financial Results and Clinical Trial Progress

Plus Therapeutics reported its Q3 2024 financial results, highlighted by progress in clinical trials and strategic partnerships.

Summary

• Plus Therapeutics announced its financial results for the third quarter of 2024, ending September 30, 2024.
• The company's cash and investments totaled $4.8 million, down from $8.6 million at the end of 2023.
• They received a $0.9 million grant payment from the Department of Defense in October 2024.
• The company expects to receive a $3.9 million grant advance from CPRIT within 90 days of this release.
• Grant revenue year-to-date was $4.4 million, compared to $3.6 million for the same period in 2023.
• The total operating loss year-to-date was $10.8 million, compared to $9.5 million in the previous year, primarily due to increased spending on the ReSPECT-LM trial.
• The net loss year-to-date was $9.1 million, or $(1.46) per basic share, compared to a net loss of $9.5 million, or $(3.54) per basic share, for the same period last year.
• The company completed enrollment in the Phase 1 ReSPECT-GBM trial and obtained FDA agreement to begin enrollment in the ReSPECT-LM multi-administration trial.
• A manufacturing partnership with SpectronRx was established to support late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and partnerships, the financial results show a decrease in cash and an increase in operating losses. This suggests a need for further funding and a cautious outlook.

Positives

• The company has secured FDA agreement to initiate a Phase 1 trial for multiple doses of Rhenium (186Re) Obisbemeda for leptomeningeal metastases.
• Positive data from the ReSPECT-GBM trial was presented at a major medical conference.
• A strategic manufacturing partnership with SpectronRx was established to support future production.
• The company received a $0.9 million grant from the Department of Defense.
• The company is on track to receive a $3.9 million grant advance from CPRIT.
• The company has expanded the ReSPECT-GBM Phase 1/2 Trial to new sites and referral regions.
• The company entered into a Research and Collaboration Agreement with Brainlab to implement optimized case planning software.
• The company obtained CLIA registration for its Houston-based facility.

Negatives

• The company's cash and investments balance decreased to $4.8 million from $8.6 million at the end of 2023.
• The total operating loss year-to-date increased to $10.8 million from $9.5 million in the previous year.
• The company's net loss year-to-date was $9.1 million, or $(1.46) per basic share.

Risks

• The company is in the early stages of product development, and clinical trial results are uncertain.
• The company's liquidity and capital resources are limited, and they may need to raise additional cash.
• There are risks associated with radiotherapeutic manufacturing, production, and distribution.
• The company faces competition within the cancer diagnostics and therapeutics field.
• The company is subject to risks associated with laws or regulatory requirements, including compliance with Nasdaq listing requirements.
• The company is subject to the risk of material security breaches or cybersecurity attacks.

Future Outlook

The company is on track to complete both Phase 1 LM trials and move to later stage trials in 2025, complete ReSPECT-GBM Phase 2 enrollment by 2025, obtain IND approval for a Phase 1/2 trial of Rhenium (186Re) Obisbemeda for pediatric ependymoma and high-grade glioma, and launch the CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay Platform as a laboratory-developed test (LDT) in 2025.

Management Comments

• Securing agreement from the FDA to initiate a Phase 1 multiple dose administration trial is a key next step in our integrated development plan for Rhenium (186Re) Obisbemeda for patients with LM, said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.
• We are on track to complete both Phase 1 LM trials and move to later stage trials in 2025.

Industry Context

This announcement reflects the ongoing efforts in the radiotherapeutics field to develop targeted treatments for difficult-to-treat cancers, particularly those of the central nervous system. The company's focus on Rhenium (186Re) Obisbemeda and its strategic partnerships align with the industry's trend towards personalized medicine and advanced drug delivery systems.

Comparison to Industry Standards

• Plus Therapeutics is developing Rhenium (186Re) Obisbemeda, a targeted radiotherapeutic, similar to companies like Actinium Pharmaceuticals (ATNM) which is developing targeted radiotherapies for hematologic cancers.
• The company's focus on central nervous system cancers is similar to companies like Kazia Therapeutics (KZIA) which is developing treatments for brain cancer.
• The company's partnership with SpectronRx for manufacturing is similar to other biotech companies that rely on contract manufacturing organizations (CMOs) to scale up production.
• The company's clinical trial progress is comparable to other companies in the early stages of drug development, with the need to demonstrate safety and efficacy in larger patient populations.
• The company's cash burn rate and operating losses are typical for a clinical-stage biotech company, but the company will need to secure additional funding to continue operations.

Stakeholder Impact

• Shareholders may be concerned about the decrease in cash and increased operating losses.
• Employees may be impacted by the company's financial situation and future funding needs.
• Patients may benefit from the company's clinical trial progress and potential new treatments.
• Suppliers and partners may be affected by the company's financial stability and future plans.
• Creditors may be concerned about the company's ability to repay debts.

Next Steps

• The company plans to present at the Society for Neuro-Oncology (SNO) Annual Conference (November 21-24, 2024).
• The company plans to present at the San Antonio Breast Cancer Symposium (December 10-13, 2024).
• The company aims to complete the ReSPECT-LM Phase 1 single dose administration trial and determine the maximum tolerated and recommended Phase 2 doses by year-end.
• The company plans to initiate the ReSPECT-LM Phase 1 multiple dose administration trial in 2025.
• The company plans to complete ReSPECT-GBM Phase 2 enrollment by 2025.
• The company plans to obtain IND approval for a Phase 1/2 trial of Rhenium (186Re) Obisbemeda for pediatric ependymoma and high-grade glioma.
• The company plans to launch the CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay Platform as a laboratory-developed test (LDT) in 2025.

Key Dates

Keywords

Rhenium (186Re) Obisbemeda, Leptomeningeal Metastases, Radiotherapeutics, Clinical Trials, CNS Cancer, SpectronRx, ReSPECT-GBM, ReSPECT-LM, Brainlab, FDA, Grant Revenue, Operating Loss